louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01699490: Role of Inflammation Factors and Insulin Resistance in Major Depressive Disorder
Official title: Role of Inflammation Factors and Insulin Resistance in the Pathophysiology and Treatment Response of Major Depressive Disorder
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Major Depressive Disorder
Keywords: Major Depressive Disorder
Antidepressants
Insulin
Fluoxetine
Lead sponsor: National Cheng-Kung University Hospital
Sponsor class: OTHER
Collaborators: name: National Science and Technology Council, Taiwan
First posted: 2012-10-03
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to identify evidence-based guidelines for treating major depressive disorder to full remission in Taiwanese major depressive disorder (MDD) patients. To achieve this goal, the investigators aim to: (1) evaluate the risks and benefits of adjunctive pharmacotherapies for cognitive and metabolic consequences in MDD, and (2) clarify the shared biological mechanisms between mood, immune and metabolism homeostasis

Detailed description: The prevalence of insulin resistance did not significantly differ among the healthy controls and drug-naïve MDD patients before and after antidepressant treatment. Meanwhile, the current study indicated that antidepressants might affect insulin secretion independently of the therapeutic effects on MDD. Therapeutic strategies considering both treatment effectiveness and glucose-insulin homeostasis in MDD patients are necessary.

Eligibility criteria: Inclusion Criteria:

* Age: 16-65 years old
* Signed informed consent by patient or legal representative
* Hamilton Rating Scale for Depression (HDRS) scores ≥ 16
* A diagnosis of MDD according to DSM-IV criteria made by a specialist in psychiatry

Exclusion Criteria:

* Monoamine oxidase inhibitor or antidepressant treatment prior to entering the study
* A DSM-IV diagnosis of substance abuse within the past three months
* An organic mental disease, mental retardation or dementia
* A serious surgical condition or physical illness
* Patients who were pregnant or breastfeeding

Primary outcomes:
measure: Hamilton Depression Rating Scale (HDRS)
timeFrame: 12 weeks
Secondary outcomes:
measure: fasting plasma glucose
timeFrame: 12 weeks
measure: fasting serum insulin
timeFrame: 12 weeks
measure: C-reactive Protein, and IL-6
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Tainan
country: Taiwan
facility: Department of Psychiatry, National Cheng-Kung University Hospital
Study officials:
affiliation: National Cheng-Kung University Hospital
name: Po See Chen, M.D., Ph.D
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03554590: DM1, Effects of Carbo-Counting on Glycemic Control
Official title: Effectiveness of Carbohydrate Counting on Glycaemic Control in T1DM Patients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Type 1 Diabetes Mellitus
Keywords: carbohydrate counting
insulin therapy
Lead sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Sponsor class: OTHER
First posted: 2018-06-13
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Carbohydrate counting is the most effective meal-planning strategy in type 1 diabetes (T1DM) to optimize insulin therapy. However, it may lead to weight gain and unhealthy eating habits. This study aims to compare glycemic control parameters, anthropometric measurements and dietary lifestyle in T1DM patients who practice CHO-counting, after attending a structured course to learn how to manage this tecnique, vs a control Group, in a follow up period of 2 years.

Detailed description: patients with type 1 DM will be enrolled in the study. patients in the intervention group will attend a 5-lessons training to learn how to manage insulin therapy depending on the amount of carbohydrates in their meals, patients in the control group will be follow according to the the standard care. after the follow up period glycometabolic, anthropometric parameters and dietary lifestyle changes will be compared between the two groups.

Eligibility criteria: Inclusion Criteria:

* type 1 diabetes mellitus
* insulin therapy
* HbA1c from 5.5 to 10%

Exclusion Criteria:

* pregnancy
* celiac disease
* hepatic impairment
* chronic renal failure

Primary outcomes:
measure: glycemic control
timeFrame: 2 years
Secondary outcomes:
measure: anthropometric parameters: BMI
timeFrame: 2 years
measure: anthropometric parameters: WAIST AND HIP CIRCUMFERENCE
timeFrame: 2 years
measure: anthropometric parameters: BIOIMPEDENTIOMETRIC PARAMETERS
timeFrame: 2 years
measure: dietary lifestyle
timeFrame: 2 years
measure: glucose variability: mean and standard deviation of self monitoring blood glucose (SMBG)
timeFrame: 2 YEARS
measure: glucose variability: incidence of hypoglycaemia
timeFrame: 2 YEARS
Other outcomes:
Locations:
city: Milan
country: Italy
facility: Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Study officials:
affiliation: FOndazione IRCCS Ca' Granda Opedale Maggiore Policlinico Milano
name: Emanuela Orsi
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01068990: Detection and Characterization of Lower Respiratory Infections in Critically Ill Patients
Official title: Detection and Characterization of Lower Respiratory Infections in Critically Ill Patients
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Severe Pneumonia
Keywords: pneumonia
Lead sponsor: Asan Medical Center
Sponsor class: OTHER
First posted: 2010-02-17
Enrollment: 300
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients admitting or admitted in medical ICU with pneumonia

Brief summary: This study is a prospective observation study for lower respiratory tract infections in medical intensive care unit. Microbiologic and clinical characteristics and outcomes of patients with severe pneumonia in medical intensive care unit will be monitored and analyzed.

Detailed description: All patients admitting medical ICU will be monitored for pneumonia. Both community-acquired (including health-care associated pneumonia) and hospital-acquired pneumonia will be included. Collecting data will include patient demographic characteristics, clinical features, microbiological characteristics including molecular work, and outcome.

Eligibility criteria: Inclusion Criteria:

* Patients admitting medical ICU with pneumonia
* Medical ICU admitted patients who is developed new pneumonia

Exclusion Criteria:

* Patients already treated more than 48 hours for pneumonia in transferring hospital and no causative organism is isolated

Primary outcomes:
measure: Identification of etiology of pneumonia
timeFrame: 7 day from the time of pneumonia diagnosis
Secondary outcomes:
measure: Pneumonia-related death
timeFrame: 1 month
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Asan Medical Center
Study officials:
affiliation: Asan Medical Center
name: Sang-Ho Choi, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04658290: Prevalence of Obstructive Sleep Apnea (OSA) and the Association With Cognitive Impairment
Official title: Prevalence of Obstructive Sleep Apnea (OSA) and the Association With Cognitive Impairment
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Obstructive Sleep Apnea
Cognitive Impairment
Lead sponsor: Chinese University of Hong Kong
Sponsor class: OTHER
First posted: 2020-12-08
Enrollment: 500
Sex: ALL
Minimum age (years): 40
Maximum age (years): 74
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Consecutive subjects are recruited from the Brain Health Longitudinal Study which was launched in July 2019. Up to 5000 subjects aged 40-74 years without a confirmed brain disorder. Participants will be assigned to undergo a portable at-home sleep study which records the airflow, heart rate, body position and oxygen saturation.

Brief summary: The study is aimed to carry out an epidemiology study investigating the prevalence of obstructive sleep apnea (OSA) and the association with cognitive impairment.


Eligibility criteria: Inclusion Criteria:

* Have stability of at least 4 weeks on permitted medications (i.e. medications known not to affect sleep architecture or circadian rhythms).

Exclusion Criteria:

* Suspected dementia or a score of \<24 on the mini-mental state examination
* A diagnosis of neurological disorders (e.g. Parkinson's Disease, Epilepsy, Multiple Sclerosis)
* Psychiatric disorders including current major depression; bipolar disorder; schizophrenia
* Other known clinically significant sleep disorders (e.g. narcolepsy)
* Been currently receiving CPAP or bi-level pressure for OSA

Primary outcomes:
measure: Number of subjects having apnea-hypopnea index of more than 5
timeFrame: 1 year
Secondary outcomes:
measure: incidence of cerebrovascular disease
timeFrame: 5 years
measure: Montreal Cognitive Assessment
timeFrame: 5 years
Other outcomes:
Locations:
city: Hong Kong
country: Hong Kong
facility: Chinese University of Hong
state: Please Select
Study officials:
References:
Clinical trial NCT01960790: Special Investigation in Patients With Intestinal Behcet's Disease (All Case Investigation)
Official title: Humira® 40mg Syringe 0.8mL Subcutaneous Injection Special Investigation in Patients With Intestinal Behcet's Disease
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Behcet's Disease
Keywords: Humira®
Behcet's Disease
Adalimumab
Lead sponsor: AbbVie
Sponsor class: INDUSTRY
First posted: 2013-10-11
Enrollment: 473
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All participants who received Humira® (Adalimumab) for the treatment of Intestinal Behcet's disease

Brief summary: This investigation was conducted to obtain the following information regarding the use of Adalimumab (Humira®) 40mg Syringe 0.8mL for Subcutaneous Injection in patients with Intestinal Behcet's Disease.

1. Incidence and conditions of occurrence of adverse reactions in clinical practice
2. Factors likely to affect the safety and effectiveness


Eligibility criteria: Inclusion Criteria:

* All patients who received Adalimumab for the treatment of Intestinal Behcet's disease (not sufficiently responsive to existing therapies, e.g. steroids, immunomodulator)

Exclusion Criteria:

Contraindications according to the Package Insert include patients who had any of the following:

* serious infections
* tuberculosis
* a history of hypersensitivity to any ingredient of Humira®
* demyelinating disease or a history of demyelinating disease
* congestive cardiac failure

Primary outcomes:
measure: Number of Participants With Adverse Drug Reactions
timeFrame: Up to Week 156
Secondary outcomes:
measure: Global Assessment of Gastrointestinal Symptoms
timeFrame: Up to Week 156
measure: Global Assessment of Gastrointestinal Symptoms of Behcet's Disease
timeFrame: Up to Week 156
measure: Number of Participants With Cardinal Symptoms of Behcet's Disease
timeFrame: Up to Week 156
measure: Number of Participants With Accessory Symptoms of Behcet's Disease
timeFrame: Up to Week 156
measure: Number of Participants With Degree of Improvement of Endoscopic Findings
timeFrame: Up to Week 156
measure: Changes in C-reactive Protein (CRP)
timeFrame: Up to Week 156
Other outcomes:
Locations:
Study officials:
affiliation: AbbVie
name: Osamu Mikami, MD
role: STUDY_DIRECTOR
References:
citation: Suzuki Y, Hagiwara T, Kobayashi M, Morita K, Shimamoto T, Hibi T. Long-term safety and effectiveness of adalimumab in 462 patients with intestinal Behcet's disease: results from a large real-world observational study. Intest Res. 2021 Jul;19(3):301-312. doi: 10.5217/ir.2020.00013. Epub 2020 Aug 20.
Clinical trial NCT00928590: Safety Study of DuoTrav APS in Patients With Open-Angle Glaucoma or Ocular Hypertension
Official title: A Twelve-Month Open-Label Safety Study of Polyquaternium-Preserved DuoTrav APS Dosed Once Daily in Patients With Open-Angle Glaucoma or Ocular Hypertension
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Open-angle Glaucoma
Ocular Hypertension
Keywords: open-angle glaucoma
ocular hypertension
pseudoexfoliation
pigment dispersion
Lead sponsor: Alcon Research
Sponsor class: INDUSTRY
First posted: 2009-06-26
Enrollment: 155
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to describe the long-term safety of a fixed combination product containing an alternative preservative, dosed once daily for 12 months, in patients with open-angle glaucoma or ocular hypertension.


Eligibility criteria: Inclusion Criteria:

* Willing and able to sign an informed consent document.
* Open-angle glaucoma or ocular hypertension who would benefit from a fixed combination medication, in the opinion of the investigator.
* Stable treatment of an IOP-lowering medication.
* Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

* Pregnant, breastfeeding, or not using adequate birth control.
* Best-corrected visual acuity (BCVA) worse than 55 ETDRS letters.
* Other protocol-defined exclusion criteria may apply.

Primary outcomes:
measure: Adverse Events (AEs)
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Alcon Research
name: Theresa Landry, Ph.D
role: STUDY_DIRECTOR
References:
Clinical trial NCT06643390: A Study of MK-2225 in Healthy Participants (MK-2225-003)
Official title: A Multiple Ascending Dose Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MK-2225 in Healthy Participants
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE1
Conditions: Systemic Sclerosis
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
First posted: 2024-10-16
Enrollment: 32
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to learn about the safety of MK-2225, including how well people tolerate it. Researchers also want to learn what happens to different doses of MK-2225 in a person's body over time.


Eligibility criteria: Inclusion Criteria:

The key inclusion criteria include but are not limited to the following:

* Is in good health before randomization
* Body Mass Index (BMI) ≤32 kg/m\^2, inclusive

Exclusion Criteria:

The key exclusion criteria include but are not limited to the following:

* History of clinically significant endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
* History of hypersensitivity to the MK-2225 drug substance, its inactive ingredients or the placebo (normal saline)

Primary outcomes:
measure: Number of Participants Who Experience an Adverse Event (AE)
timeFrame: Up to approximately 20 weeks
measure: Number of Participants Who Discontinue Study Treatment Due to an AE
timeFrame: Up to approximately 8 weeks
Secondary outcomes:
measure: Maximum Plasma Concentration (Cmax) of MK-2225
timeFrame: At designated timepoints (up to approximately 16 weeks)
measure: Lowest Plasma Concentration (Ctrough) of MK-2225
timeFrame: At designated timepoints (up to approximately 16 weeks)
measure: Time to Maximum Plasma Concentration (Tmax) of MK-2225
timeFrame: At designated timepoints (up to approximately 16 weeks)
measure: Area Under the Concentration-Time Curve from Time 0 to Tau (AUC0-τ) of MK-2225
timeFrame: At designated timepoints (up to 16 approximately weeks)
measure: Apparent Terminal Half-life (t1/2) of MK-2225
timeFrame: At designated timepoints (up to approximately 16 weeks)
measure: Mean Accumulation Ratio of MK-2225
timeFrame: At designated timepoints (up to approximately 16 weeks)
Other outcomes:
Locations:
city: Miami
country: United States
facility: Clinical Pharmacology of Miami (Site 0002)
state: Florida
city: Springfield
country: United States
facility: Bio-Kinetic Clinical Applications, LLC dba QPS-MO (Site 0004)
state: Missouri
Study officials:
affiliation: Merck Sharp & Dohme LLC
name: Medical Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT00918190: Late Onset Postoperative Nausea and Vomiting
Official title: Late Onset Postoperative Nausea and Vomiting Following Strabismus Surgery in Pediatric.What Combination is Better
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Postoperative Nausea and Vomiting
Keywords: Postoperative nausea and vomiting
Pediatric
Strabismus
Late onset postoperative nausea and vomiting
Lead sponsor: King Khaled Eye Specialist Hospital
Sponsor class: OTHER_GOV
First posted: 2009-06-11
Enrollment: 75
Sex: ALL
Minimum age (years): 4
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this trial is to study the effects of different combinations of antiemetics on the incidence of late onset postoperative nausea and vomiting.

Detailed description: The authors will study the effect of many antiemetics on the occurrence of nausea and vomiting following strabismus surgery in pediatrics.

Eligibility criteria: Inclusion Criteria:

* children undergoing elective strabismus surgery under general anesthesia

Exclusion Criteria:

* children experienced retching or vomiting
* children who have taken anti-emetic medications, antihistaminics, steroids, or psychoactive drugs within 24 hours before surgery

Primary outcomes:
measure: Efficacy of antiemetics combination
timeFrame: 3 days
Secondary outcomes:
Other outcomes:
Locations:
city: Riyadh
country: Saudi Arabia
facility: king Khaled Eye Specialist hospital
Study officials:
affiliation: King Khaled Eye Specialist Hospital
name: Waleed Riad, MD, AB, SB
role: PRINCIPAL_INVESTIGATOR
References:
citation: Riad W, Altaf R, Abdulla A, Oudan H. Effect of midazolam, dexamethasone and their combination on the prevention of nausea and vomiting following strabismus repair in children. Eur J Anaesthesiol. 2007 Aug;24(8):697-701. doi: 10.1017/S0265021507000166. Epub 2007 Apr 17.
Clinical trial NCT03107390: Evaluation of NT-proBNP in Chronic Inflammatory Bowel Disease
Official title: Evaluation of NT-proBNP in Chronic Inflammatory Bowel Disease
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Inflammatory Bowel Diseases
NT-pro-BNP
Lead sponsor: Centre Hospitalier Universitaire, Amiens
Sponsor class: OTHER
First posted: 2017-04-11
Enrollment: 159
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: NT-proBNP is a major diagnostic and prognostic marker in cardiology, but it is also a new marker for biological inflammation, especially in rheumatology.

Its evaluation in chronic inflammatory bowel disease was carried out in a preliminary study, the OPERA study where in a population of 12 patients showed an increase in NT-proBNP correlated with the biological and endoscopic activity of the disease. This larger study is therefore a pilot study that could see NTproBNP as a new biomarker of inflammation in MICI.


Eligibility criteria: Inclusion Criteria:

* Adult subjects (age 18 years)
* MICI Group: Patients monitored for probable HC or MC
* Control group: Patients referred for consultation in gastroenterology with a clinical and endoscopic picture eading to the diagnosis of TF I
* Person who agreed to participate in the study
* Patient covered by social insurance

Exclusion Criteria:

* Causes of increased concentrations of natriuretic peptides: acute heart failure, acute or chronic pulmonary disease with right ventricular repercussion, valvulopathies, primary or secondary HVG, atrial fibrillation cardiac arrhythmia, chronic systolic dysfunction, hyperthyroidism, Addison's disease, hyperaldosteronism Primary, diabetes, cirrhosis with ascites, cancers, chronic renal insufficiency.
* Inflammatory and autoimmune diseases (excluding MC and RCH), chronic inflammatory syndrome
* Ongoing treatment that may affect the concentration of natriuretic peptides: ACE inhibitor, angiotensin II receptor antagonists, diuretics
* Patient deprived of liberty or protected major (under guardianship or curatorship)

Primary outcomes:
measure: Blood level of NTproBNP.
timeFrame: 1 month
Secondary outcomes:
Other outcomes:
Locations:
city: Amiens
country: France
facility: CHU Amiens Picardie
state: Picardie
Study officials:
References:
Clinical trial NCT05278390: Automated Quantification of Radiologic Pulmonary Alteration During Acute Respiratory Failure: Application to the COVID-19 Pandemic
Official title: Automated Quantification of Radiologic Pulmonary Alteration During Acute Respiratory Failure: Application to the COVID-19 Pandemic : Prospective Multicenter Cohort Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: SARS-CoV-2 Infections
Respiratory Failure With Hypoxia
Lead sponsor: University Hospital, Strasbourg, France
Sponsor class: OTHER
Collaborators: name: REGION GRAND EST
name: E-MEDIA
name: VISIBLE PATIENT
First posted: 2022-03-14
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Automated quantification of the pulmonary volume impaired during acute respiratory failure could be helpful to assess patient severity during COVID-19 infection or perioperative medicine, for example.

This study aims at assessing the correlation between the amount of radiologic pulmonary alteration and the clinical severity in two clinical situation :

1. SARS-CoV-2 infections
2. Postoperative hypoxemic acute respiratory failure.


Eligibility criteria: Inclusion Criteria:

* Subject admitted to a care unit of the University Hospitals of Strasbourg or the University Hospital of Nancy and presenting a suspicion of SARS-CoV-2 infection or postoperative hypoxemic respiratory failure
* Able to understand the objectives and risks of the research and to give dated and signed informed consent.

Subjects may also be included in emergency or immediate life-threatening situations.

* Subject with insurance covering

Exclusion Criteria:

* Pregnant woman (pregnancy confirmed by a urine or blood test)
* Subject usually on home oxygen therapy
* Subject under court protection
* Subject under guardianship or curatorship

Primary outcomes:
measure: Correlation between altered pulmonary volume and ordinal severity scale
timeFrame: 2 days after CT scan (Day 2)
Secondary outcomes:
measure: Correlation between altered pulmonary volume and ordinal severity scale
timeFrame: 7 days after CT scan (Day 7)
measure: Mortality
timeFrame: 90 days following CT scan (Day 90)
measure: Rate of admission to intensive care unit
timeFrame: 28 days following CT scan (Day 28)
measure: Initial length of hospitalization stay (in days)
timeFrame: 90 days following CT scan (Day 90)
Other outcomes:
Locations:
city: Nancy
country: France
facility: Service d'anesthésie réanimation-CHU de Nancy
city: Strasbourg
country: France
facility: Service d'Anesthésie-Réanimation - CHU Strasbourg
Study officials:
References: